Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease

cAMP, cGMP and Amyloid β: Three Ideal Partners for Memory Formation

(2018) Roberta Ricciarelli et al.   TRENDS IN NEUROSCIENCES

Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease

(2017) Jos Prickaerts et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

On the path to 2025: understanding the Alzheimer’s disease continuum

(2017) Paul S. Aisen et al.   Alzheimers Research & Therapy

2016 Alzheimer's disease facts and figures

(2016)   Alzheimers & Dementia

First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males

(2016) Viktoria Moschetti et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Prevalence and Incidence of Dementia Due to Alzheimer’s Disease: a Systematic Review and Meta-Analysis

(2016) Kirsten M. Fiest et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Improving synaptic plasticity and cognitive function in rodents by the novel phosphodiesterase 9A inhibitor bi 409306

(2015) Holger Rosenbrock et al.   Alzheimers & Dementia

A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer’s Disease

(2014) Elias Schwam et al.   Current Alzheimer Research

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Revising the definition of Alzheimer's disease: a new lexicon

(2010) Bruno Dubois et al.   LANCET NEUROLOGY

Selective phosphodiesterase inhibitors: a promising target for cognition enhancement

(2008) Olga A. H. Reneerkens et al.   PSYCHOPHARMACOLOGY